Clinical Trial Update: Study Assessing RLT Using [177Lu]Lu-PentixaTher for Relapsed/Refractory CXCR4+ Acute Leukemia. [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update outlines a Phase 1/2 study evaluating radioligand therapy with [177Lu]Lu-PentixaTher targeting CXCR4 in relapsed/refractory acute leu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia

Drugs mentioned

• [177Lu]Lu-PentixaTher (pentixafor labeled with lutetium-177)

Snippet

Sponsor: Nantes University Hospital | Conditions: Acute Leukemia | Phase 1, Phase 2 | Status: RECRUITING